IsoPlexis has installed its ground-breaking IsoLight benchtop system at Fred Hutchinson Cancer Research Center, as part of the company's Early Adopter Program. The sample-to-answer IsoLight benchtop system analyzes IsoPlexis' IsoCode chip to provide clinical and translational researchers a powerful, yet straightforward solution for establishing immune response functional correlates with outcome in key therapeutic areas like CAR-T and other cellular immunotherapies. The IsoCode Chip was recognized as The Scientist's and Fierce Life Science's #1 innovation of 2017 for its ability to provide both single-cell sensitivity and highly multiplexed and quantitative functional ELISA detection together for the first time. The data from the IsoCode Chip demonstrates improved capacity in predicting CAR-T patient responses pre-infusion compared to existing technologies. The integration of precision imaging and fluidics with user-friendly software makes it an easy-to-use instrument yielding highly dimensional, single-cell proteomic data.
The announced collaboration between Nektar and IsoPlexis is focused on further defining the functional impact of Nektar's cytokine agonist NKTR-214 in the clinic, at the single-cell level using IsoPlexis' platform with the goal of revealing both mechanism and potential immune correlates with outcome. Recently, preclinical data captured by IsoPlexis' IsoCode Chip in a study led by UCLA (AACR 2018) provided evidence that Nektar's cytokine agonist NKTR-214 can significantly boost the activation of critical T cell subsets, termed polyfunctional T cells, in combination with adoptive cell transfer (ACT) therapies. Through this collaboration, IsoPlexis will employ its IsoCode Chip's single-cell functional profiling in collaboration with Nektar Therapeutics to profile the effects of NKTR-214 in both monotherapy and combination immunotherapy in a clinical setting.
FOCiS 2018 Day 2: Cancer Vaccine Correlates Revealed through Single-Cell Function
On Day 2 of the FOCiS 2018 Annual Meeting, IsoPlexis presented "Single-cell Polyfunctionality of CD4+ T Cells Shows Promise as a Predictor of Overall Survival of Pancreatic Cancer Patients Treated with GVAX Vaccine". The presented data demonstrates: (1) Single-cell multiplexed proteomic profiling provides a comprehensive assessment of T cell function and identifies PSI change between pre- and post-vaccination CD4+ T cells as a novel correlate to OS in pancreatic cancer patients with GVAX treatment; (2) Novel visualization methods reveal a diverse landscape of polyfunctional response by GVAX vaccination, providing a precise platform for capturing efficacy and durability data for therapy development; (3) These novel biomarker capture and analysis methods have the potential to guide more sensitive and potentially predicative quality assessments, which may enable vaccines with more efficacious and persistent profiles. FOCIS is a leading conference in translational immunology where clinicians and researchers deliver the latest breakthroughs across immune-mediated diseases.
FOCiS 2018 Day 1: Cancer Vaccine Correlates Revealed through Single-Cell Function
On Day 1 of the FOCiS 2018 Annual Meeting, IsoPlexis presented "Single-cell Highly Multiplexed Proteomics Identifies Novel Polyfunctional Human CD8+ T Cell Signatures Induced by a Nanoparticle-Based Melanoma Vaccine in Human Immune System Mice". The presented data demonstrates: (1) Nanoparticle-based melanoma vaccine demonstrates capability to induce potent antigen specific human CD8+ T cell response in HIS mice; (2) IsoPlexis’ novel single-cell heatmap and PAT PCA visualizations reveal distinct polyfunctional cell profiles with these combinations human cytokine secretions that drive human CD8+ T cell response by NP vaccine in HIS mice. This IsoPlexis’ platform further dissects the full spectrum of immune cell function and more accurately assesses human CD8+ T cells induced by NP vaccine in HIS mice; (3) The polyfunctional human CD8+ T cell responses sensitively demonstrates successful induction of tumor vaccine, which may enhance accurate evaluation of tumor vaccine efficacy in pre-clinical setting. FOCiS is a leading conference in translational immunology where clinicians and researchers deliver the latest breakthroughs across immune-mediated diseases.
Joint Publication with Kite Pharma and NCI in Blood Journal: Preinfusion Polyfunctional Anti-CD19 Chimeric Antigen Receptor T Cells Associate with Clinical Outcomes in NHL
Research recently published in the journal Blood -- conducted in a collaborative effort with Kite Pharma, a Gilead company -- demonstrates a significant association between the functionality of an anti-CD19 CAR-T cell product before treatment, as defined by IsoPlexis' Polyfunctional Strength Index (PSI), and the objective response in patients with non-Hodgkin lymphoma (NHL). "The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy before treatment, as well as to improve both pre-infusion product potency testing and guide cell product optimization.
IsoPlexis Recognized with the Pharma Tech Outlook Cover Story as Top 10 Analytics Solution Provider in 2018
IsoPlexis’ analytics platform was recognized by Pharma Tech Outlook as the cover story for the Top 10 Analytics Solution Providers in 2018! The award focuses on IsoPlexis' IsoSpeak software suite's ability to clarify results, reports, and associations from large, complex patient data sets, to deliver better data by which to determine effective cancer immunotherapies. The Pharma Tech Outlook article emphasizes the ability to capture a previously unseen 42 different secreted functional proteins per cell, across thousands of single cells simultaneously. The IsoSpeak software speak was awarded this distinction for the ability to understand the large scale of data generated, which enables researchers to generate a precise, functional patient profile from this data, and compare large groups of patients in a comprehensible and actionable fashion.
AACR 2018 Day 3: Increased polyfunctionality observed in samples treated with ACT+NKTR-214 vs ACT+IL-2
On day 3 of the AACR 2018 Annual Meeting in Chicago, IsoPlexis scientific advisory board member Antoni Ribas, director of the tumor immunology program at UCLA's Jonsson Comprehensive Cancer Center, presented "Enhanced expansion and tumor targeting of adoptively transferred T cells with NKTR-214". He highlighted findings from a study looking at the effectiveness of ACT in combination with the cytokine agonist NKTR-214, produced by San Francisco-based biopharma company Nektar Therapeutics, which also participated in the study. The study found that the ACT-NKTR-214 combination improved the induction of cytotoxic T cells and increased their polyfunctionality, indicating that addition of NKTR-214 could boost the performance of ACT.
IsoPlexis’ New IsoLight Instrument Receives the Red Dot Design Award for Highest Design Quality
IsoPlexis’ new IsoLight instrument, capable of gathering predictive information at the single-cell level, received the highly coveted distinction “Red Dot” for excellence in design. The IsoLight sample-to-answer instrument received the Red Dot Design Award for high design quality and focus on the user experience within the life sciences instrumentation category. The IsoLight's integrated design combines precision imaging and fluidics with a user-friendly software interface to create a uniquely easy to use single-cell system. The Red Dot Award in Product Design has roots dating back to 1955 and determines the best products created each year. True to the motto “In search of good design and innovation”, a jury comprising roughly 40 members assessed the products individually based on the original. The strict judging criteria, which include level of innovation, functionality, formal quality, ergonomics and durability, provide a frame of reference which the jurors then complement with their own expertise.
TRCCC 2018: Single-Cell TILs Polyfunctionality Associates with Clinical Outcome of Anti-PD-1 Therapy
IsoPlexis presented "Single-Cell Cytokine Profiling of Tumor-Infiltrating T Cells to Measure Patient Responses to Anti-PD-1 Therapy" at the Translational Research Cancer Centers Consortium (TRCCC) 2018 in Seven Springs, PA. The study found an association between CD8+ TILs polyfunctionality and the clinical outcome of melanoma patients on Anti-PD-1 therapy. TRCCC works to expedite the progress in immunotherapy and other biologic therapies. TRCCC brings together leaders in this field to advance science, collaboration and clinical trials to help individuals diagnosed with cancer.
ASCO-SITC 2018 Day 1: Increase in Polyfunctionality Observed Post Intratumoral Injection of TLR4 Agonist G100
On Day 1 of the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium, in San Francisco, CA, IsoPlexis presented new data from a collaboration with Fred Hutch. The poster presentation highlighted that intratumoral (IT) injections of the toll-like receptor 4 (TLR4) agonist G100 induce a clinical response and a T cell response locally and systemically. The ASCO-SITC Clinical Immuno-Oncology Symposium is a three-day meeting which focuses on clinical and translational advances in immuno-oncology, offering new insights on the application of immunotherapy in melanoma, lung cancer, genitourinary cancers, head and neck cancer, and hematologic malignancies.
ASH 2017 Day 1: Synergistic impact of antigen and rimiducid-dependent stimulatory signals on promoting polyfunctional GoCAR-T cells targeting prostate stem cell antigen (PSCA)
On Day 1 of the ASH 2018 Annual Meeting, IsoPlexis presented "Single-cell multiplex proteomics reveals synergistic impact of antigen and rimiducid-dependent stimulatory signals on promoting polyfunctional GoCAR-T cells targeting prostate stem cell antigen (PSCA)". The presentation highlighted how IsoCode Chip, IsoPlexis' core technology developed to detect cellular responses at the single-cell level, was used to assess functional response to prostate stem cell antigen (PSCA) with Bellicum's proprietary GoCAR-T products targeting PSCA-expressing solid tumors. The single-cell polyfunctional metrics may provide insights into quality check of pre-infusion CAR-T cell products and potential biomarker discovery to predict efficacy, persistence and safety of CAR-T cell therapy in solid tumor. ASH is a leading conference in hematology where clinicians and researchers deliver the latest breakthroughs across blood-related diseases.
IsoPlexis' IsoCode Chip and IsoLight Platform won the 2017 Fierce Innovation Award for Technology Innovation in the life sciences industry. "It is an honor to receive this award from the publishers of FierceBiotech and FiercePharma," said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. The Fierce Innovation Awards: Life Sciences Edition is presented annually by the publishers of FierceBiotech and FiercePharma to highlight outstanding innovations in different categories, including technology, that are driving improvements and transforming the life sciences field. An expert panel of judges reviewed all submissions and scored them based on their potential to make the greatest impact for biotech and pharmaceutical companies. The Technology Innovation category highlights products and services that are using innovative technology solutions to better serve the life sciences industry and promote innovation.
IsoPlexis' IsoCode Chip, its next-generation technology capable of identifying and predicting patient responses to immunotherapy, was recognized as the top innovation of 2017 by The Scientist. IsoPlexis’ single-cell technology was recognized as a detection system poised to revolutionize clinical research and advance scientific knowledge. The Scientist’s jury member Cruickshaw-Quinn stated: “The IsoLight single-cell technology, with its ease-of-use, has the potential to impact cancer research for both biomarker discovery and patient monitoring.”
Journal for ImmunoTherapy of Cancer Highlights New Single Cell Bioinformatics Tools From IsoPlexis Used To Characterize Differences in CAR-T Products
IsoCode, IsoPlexis’ single-cell precision platform, captured novel data from CAR-T products developed by Novartis Pharmaceuticals (Novartis), leading to IsoPlexis' development of new bioinformatics tools for visualizing high-dimensional, single-cell proteomics data. These new tools enable researchers to better compare key differences between products, and more easily analyze highly-multiplexed, single CAR-T cell functional profiles to gain insight into CAR-T product potency and cytokine mediated immuno-toxicity. Researchers used IsoCode to analyze genetically re-engineered CAR-T cells designed to target CD19, a promising treatment for B-cell malignancies, including most cases of non-Hodgkin lymphoma and some types of leukemia. The large quantity of precise, high-quality data required IsoPlexis to develop new bioinformatics tools, which researchers used to better visualize the polyfunctional profiles of each individual CAR-T product.